Search filters

List of works by Laurent Garderet

A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation

scientific article published on 01 February 2002

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

scientific article published on 23 November 2010

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

scientific article published on 13 October 2009

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

scientific article published on 11 April 2014

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

scientific article

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

scientific article published on 14 April 2016

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

scientific article published on 12 March 2018

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

scientific article published on 12 March 2013

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

scientific article published on 2 November 2009

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

scientific article published on 17 August 2011

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

scientific article

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

scientific article published on 24 June 2013

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data

scientific article

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

scientific article published on 20 June 2022

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

scientific article published on 25 December 2019

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

scientific article

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

scientific article

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

scientific article

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

scientific article

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

scientific article published on 5 January 2007

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

scientific article published on 22 February 2020

Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients

scientific article published on 13 August 2019

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

scientific article

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

scientific article published on 01 August 2018

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

scientific article

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

scientific article published on 16 October 2020

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

scientific article published on 01 May 2012

Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis

scientific article published on 31 December 2013

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

scientific article published on April 2017

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

scientific article published on 27 July 2006

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Multiple myeloma with clivus involvement, neurological symptoms, and 45 g/L proteinorachia

scientific article published on 30 September 2019

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

scientific article published on 11 March 2014

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

scientific article published on 14 November 2014

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

scientific article published on 9 January 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

scientific article

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

scientific article published on 03 October 2018

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

scientific article published on 2 May 2018

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

scientific article published on 07 July 2017

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

scientific article published on 19 August 2020

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

scientific article

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

scientific article published on 12 January 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

scientific article

The translocation t(4;14) can be present only in minor subclones in multiple myeloma

scientific article published on 15 July 2013

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

scientific article

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

scientific article published on 20 June 2016

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

scientific article

Paulina is supported by:

About Paulina

Help